Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer

Natsuko Chiba; Takashi Yoshioka; Shunsuke Kato; Shin Takahashi; Hiroyuki Shibata; Satoshi Kato; Masato Sakayori; Kazunori Otsuka; Yuichi Kakudo; Hisatsugu Ohori; Gengo Yamaura; Masanobu Takahashi; Katsuhiro Yasuda; Chikashi Ishioka

Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer

Natsuko Chiba, Takashi Yoshioka, Shunsuke Kato, Shin Takahashi, Hiroyuki Shibata, Satoshi Kato, Masato Sakayori, Kazunori Otsuka, Yuichi Kakudo, Hisatsugu Ohori, Gengo Yamaura, Masanobu Takahashi, Katsuhiro Yasuda, Chikashi Ishioka

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (I-LV) in 50 patients with advanced or recurrent colorectal cancer in our institute. The dose of 5-FU was 600 mg/m2 and the dose of l-LV was 250 mg/m2. Objective response were 36.8% of patients who had administration of full-dose and 14.8% of patients who had the administration of reduced dose or prolonged interval. No significant difference was observed in clinical benefit rates between patients administrated in full-dose and patients in reduced dose or prolonged interval. Median survival time (MST) of patients in reduced dose or prolonged interval is longer than patients in full-dose. These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval.

Original language	English
Pages (from-to)	991-995
Number of pages	5
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	32
Issue number	7
Publication status	Published - 2005 Jul

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Chiba, N., Yoshioka, T., Kato, S., Takahashi, S., Shibata, H., Kato, S., Sakayori, M., Otsuka, K., Kakudo, Y., Ohori, H., Yamaura, G., Takahashi, M., Yasuda, K., & Ishioka, C. (2005). Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 32(7), 991-995.

Chiba, N, Yoshioka, T, Kato, S, Takahashi, S, Shibata, H, Kato, S, Sakayori, M, Otsuka, K, Kakudo, Y, Ohori, H, Yamaura, G, Takahashi, M, Yasuda, K & Ishioka, C 2005, 'Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 32, no. 7, pp. 991-995.

@article{e8131b19a8224c57aa009085b674a6b6,

title = "Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer",

abstract = "The aim of this study was to evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (I-LV) in 50 patients with advanced or recurrent colorectal cancer in our institute. The dose of 5-FU was 600 mg/m2 and the dose of l-LV was 250 mg/m2. Objective response were 36.8% of patients who had administration of full-dose and 14.8% of patients who had the administration of reduced dose or prolonged interval. No significant difference was observed in clinical benefit rates between patients administrated in full-dose and patients in reduced dose or prolonged interval. Median survival time (MST) of patients in reduced dose or prolonged interval is longer than patients in full-dose. These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval.",

author = "Natsuko Chiba and Takashi Yoshioka and Shunsuke Kato and Shin Takahashi and Hiroyuki Shibata and Satoshi Kato and Masato Sakayori and Kazunori Otsuka and Yuichi Kakudo and Hisatsugu Ohori and Gengo Yamaura and Masanobu Takahashi and Katsuhiro Yasuda and Chikashi Ishioka",

year = "2005",

month = jul,

language = "English",

volume = "32",

pages = "991--995",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "7",

}

TY - JOUR

T1 - Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer

AU - Chiba, Natsuko

AU - Yoshioka, Takashi

AU - Kato, Shunsuke

AU - Takahashi, Shin

AU - Shibata, Hiroyuki

AU - Kato, Satoshi

AU - Sakayori, Masato

AU - Otsuka, Kazunori

AU - Kakudo, Yuichi

AU - Ohori, Hisatsugu

AU - Yamaura, Gengo

AU - Takahashi, Masanobu

AU - Yasuda, Katsuhiro

AU - Ishioka, Chikashi

PY - 2005/7

Y1 - 2005/7

N2 - The aim of this study was to evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (I-LV) in 50 patients with advanced or recurrent colorectal cancer in our institute. The dose of 5-FU was 600 mg/m2 and the dose of l-LV was 250 mg/m2. Objective response were 36.8% of patients who had administration of full-dose and 14.8% of patients who had the administration of reduced dose or prolonged interval. No significant difference was observed in clinical benefit rates between patients administrated in full-dose and patients in reduced dose or prolonged interval. Median survival time (MST) of patients in reduced dose or prolonged interval is longer than patients in full-dose. These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval.

AB - The aim of this study was to evaluate the efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (I-LV) in 50 patients with advanced or recurrent colorectal cancer in our institute. The dose of 5-FU was 600 mg/m2 and the dose of l-LV was 250 mg/m2. Objective response were 36.8% of patients who had administration of full-dose and 14.8% of patients who had the administration of reduced dose or prolonged interval. No significant difference was observed in clinical benefit rates between patients administrated in full-dose and patients in reduced dose or prolonged interval. Median survival time (MST) of patients in reduced dose or prolonged interval is longer than patients in full-dose. These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval.

UR - http://www.scopus.com/inward/record.url?scp=22844447405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844447405&partnerID=8YFLogxK

M3 - Article

C2 - 16044961

AN - SCOPUS:22844447405

VL - 32

SP - 991

EP - 995

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -

Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this